Associated Genetic Biomarkers

Overview

NCI Definition: One of the most common malignant tumors afflicting men. The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes. Adenocarcinomas represent the overwhelming majority of prostatic carcinomas. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. [1]

Prostate carcinomas most frequently harbor alterations in TP53, TMPRSS2, ERG, PTEN, and AR [2].

Most Commonly Altered Genes in Prostate Carcinoma

TMPRSS2-ERG Fusion, TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, and AR Amplification are the most common alterations in prostate carcinoma [2].

Top Alterations in Prostate Carcinoma

Biomarker-Directed Therapies

Significant Genes in Prostate Carcinoma

AKT1 +

AKT2 +

AKT3 +

ALK +

ARID1A +

ATM +

ATR +

ATRX +

AXL +

BACH1 +

BARD1 +

BRAF +

BRCA1 +

BRCA2 +

BRIP1 +

C11ORF30 +

CCND1 +

CDK12 +

CDK4 +

CDKN2A +

CHEK1 +

CHEK2 +

CRKL +

EGFR +

ERBB2 +

ERCC2 +

ERCC3 +

ERCC4 +

ERCC5 +

ERCC6 +

FANCA +

FANCB +

FANCC +

FANCD2 +

FANCE +

FANCF +

FANCG +

FANCI +

FANCL +

FANCM +

FLT1 +

FLT3 +

FLT4 +

GEN1 +

HDAC1 +

HDAC2 +

HRAS +

IDH1 +

IDH2 +

KDR +

KIT +

KRAS +

MCPH1 +

MDM2 +

MDM4 +

MET +

MLF1 +

MLH1 +

MLH3 +

MRE11A +

MSH2 +

MSH3 +

MSH6 +

MTAP +

MTOR +

MUTYH +

MYC +

NBN +

NPM1 +

NRAS +

NTRK1 +

NTRK2 +

NUTM1 +

PALB2 +

PARP1 +

PARP2 +

PDGFRA +

PIK3CA +

PIK3CB +

PIK3CG +

PIK3R1 +

PIK3R2 +

PMS1 +

PMS2 +

POLE +

PPP2R1A +

PPP2R2A +

PTEN +

RAD50 +

RAD51 +

RAD51B +

RAD51C +

RAD51D +

RAD54L +

RB1 +

RET +

RICTOR +

ROS1 +

RPTOR +

SLX4 +

SMARCB1 +

STAG2 +

STK11 +

TEK +

TP53 +

TSC1 +

TSC2 +

WNT5A +

XRCC1 +

Disease Details

Synonyms
Metastatic prostate cancer, Prostate cancer (NOS), Carcinoma of the Prostate, Prostate cancer, NOS, Prostate Cancer, Cancer of Prostate, Carcinoma of Prostate, Cancer of the Prostate
Parent(s)
Malignant Prostate Neoplasm
Children
Prostate Adenocarcinoma, Prostate Undifferentiated Carcinoma, Prostate Adenosquamous Carcinoma, Prostate Squamous Cell Carcinoma, Prostate Adenoid Cystic Carcinoma, Prostate Basal Cell Carcinoma, Prostate Neuroendocrine Carcinoma, and Primary Prostate Urothelial Carcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.